/ / EN
JOINT WEBSITE OF THE HONG KONG THORACIC SOCIETY AND THE CHEST DELEGATION HONG KONG AND MACAU
back to home

Coronavirus disease 2019 (COVID-19)

Management

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Lancet. 2023 Jan 28;401(10373):281-293

Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial
Clin Infect Dis. 2023 Jan 13;76(2):185-191
 
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
NEJM
N Engl J Med. 2022 Dec 28 : NEJMoa2208822. Published online 2022 Dec 28
 
Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
JAMA 2022 Dec; 5(12): e2244505. Published online1 December 2022

Effect of fluvoxamine on outcomes of nonhospitalized patients with
COVID-19: A systematic review and meta-analysis
J Infect Public Health. 2022 Oct 13;15(11):1259-1264

Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial
JAMA. 2022 Sep 27;328(12):1212-1222

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
N Engl J Med. 2022 Sep 15;387(11):1047-1049
 
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
N Engl J Med. 2022 Sep 15;387(11):1045-1047

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med. 2022 Sep 7;S2213-2600(22)00297-1

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
N Engl J Med. 2022 Sep 1;387(9):790-798.

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Circulation. 2022 Aug 29

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Lancet Infect Dis. 2022 Aug 24;22(12):1681-1693

Effects of Chinese medicine for COVID-19 rehabilitation: a multicenter observational study
Chin Med. 2022 Aug 22;17(1):99

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Lancet. 2022 Jul 30;400(10349):359-368
 
Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial
Sci Rep. 2022 Jul 12;12(1):11252

Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial
JAMA. 2022 Jun 7;327(21):2104-2113.
 
Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial
JAMA Intern Med. 2022 Jun 1;182(6):612-621.
 
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
Lancet. 2022 May 21;399(10339):1941-1953.

Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation
J Antimicrob Chemother. 2022 May 10;dkac144.

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
JAMA. 2022 Apr 5;327(13):1247-1259
 
Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE)
BMJ. 2022 Mar 23;376:e068585

Inhaled corticosteroids for the treatment of COVID‐19
Cochrane library 09 March 2022

 Anticoagulants for people hospitalised with COVID‐19
Cochrane library 04 March 2022

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Lancet. 2022 Feb 12;399(10325):665-676.
  
Efficacy and safety of short-wave diathermy treatment for moderate COVID-19 patients: a prospective, double-blind, randomized controlled clinical study
Eur J Phys Rehabil Med. 2022 Feb;58(1):137-143
 
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2
Cureus. 2022 Feb 20;14(2):e22404.

Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19The RECOVERY-RS Randomized Clinical Trial
JAMA. 2022 Feb 8;327(6):546-558.
 
Lianhua Qingwen Capsules Reduced the Rate of Severity in Patients with COVID-19: A System Review and Meta-Analysis of Randomized Controlled Trials
Evid Based Complement Alternat Med. 2022 Feb 2;2022:9617429
 
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
CMAJ. 2022 Feb 22;194(7):E242-E251.
 
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
Gut. 2022 Feb 10;gutjnl-2022-326952.

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19
A Randomized Clinical Trial
JAMA. 2021 Dec 7;326(21):2161-2171
 
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
N Engl J Med. 2021 Dec 16;NEJMoa2116044

Effect of 12mg vs 6mg of Dexamethasone on the Number of Days Alive
Without Life Support in Adults With COVID-19 and Severe Hypoxemia
The COVID STEROID 2 Randomized Trial
JAMA. 2021;326(18):1807-1817
 
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Lancet Glob Health. 2022 Jan;10(1):e42-e51.

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial
Lancet Respir Med. 2021 Aug 20;S2213-2600(21)00356-8

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
N Engl J Med. 2021 Aug 26;385(9):777-789
 
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
N Engl J Med. 2021 Aug 26;385(9):790-802.

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection. A Randomized Clinical Trial
JAMA. 2021 Aug 10;326(6):490-498
 
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. A Meta-analysis.
JAMA. 2021 Aug 10;326(6):499-518

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial   
Lancet Respir Med. 2021 Aug;9(8):863-872
 
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2103417. Online ahead of print.
 
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19  
N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2105911. Online ahead of print

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19  
Ann Intern Med. 2021 Jul 13;M21-0653. doi: 10.7326/M21-0653. Online ahead of print.

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
Lancet Rheumatol. 2021 Jul;3(7):e498-e506.
 
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial
Lancet Respir Med. 2021 Jul;9(7):755-762
 
Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis
Int Immunopharmacol. 2021 Jul; 96:107732
 
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
N Engl J Med 2021; 385:406-415
 
Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis
J Endocrinol Invest. 2021 Jun 24 : 1–16.
 
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2021 May 1;397(10285):1637-1645
 
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
Lancet Diabetes Endocrinol. 2021 May;9(5):293-303

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial
BMC Infect Dis. 2021 Apr 10;21(1):337.
 
Inhaled budesonide in the treatment of early COVID-19
The Lancet Respiratory Medicine 9 April 2021
 
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Lancet 2021 May 29;397(10289):2049-2059

Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women.
JAMA. 2021 May 13.

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure. : The HENIVOT Randomized Clinical Trial.
JAMA. 2021;325(17):1731-1743

Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis
Thorax 2021;76:479-486

Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021 Apr 13;325(14):1426-1435
 
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 Feb 25.
Should Remdesivir be used for the treatment of patients With COVID-19? Rapid, living practice points from the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 09

Pregnancy, postpartum care, and COVID-19 vaccination in 2021. JAMA. 2021 Feb 08

Joint Scientific Committee on Emerging and Zoonotic Disease and Scientific Committee on Vaccine Preventable Diseases. Consensus on the use of BNT162b2 among frail elderly in Hong Kong (as of 8 February 2021). Hong Kong: Centre for Health Protection; 2021 Feb 8.

Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis. 
EClinicalMedicine. 2021 Feb 13

Scientific Committee on Emerging and Zoonotic Diseases and Scientific Committee on Vaccine Preventable Diseases. Consensus interim recommendations on the use of CoronaVac in Hong Kong (as of February 19, 2021). Hong Kong: Centre for Health Protection; 2021 Feb.

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021 Jan 06.

Scientific Committee on Emerging and Zoonotic Diseases and Scientific Committee on Vaccine Preventable Diseases. Consensus interim recommendations on the use of COVID-19 vaccines in Hong Kong (as of Jan 7, 2021). Hong Kong: Centre for Health Protection; 2021 Jan 21.

Critically Ill Patients with COVID-19: A Narrative Review on Prone Position. Pulm Ther. 2020 Dec;6(2):233-246.

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020 Dec 11.

Critically Ill Patients with COVID-19: A Narrative Review on Prone Position. Pulm Ther. 2020 Dec;6(2):233-246.

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020 Dec 14;24(1):696.

Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Ann Intern Med. 2020 Oct 05.

Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020 Oct 08.

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Sep 02.

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Sep 02.

Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-787.

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate cOVID-19: a randomized clinical trial. JAMA. 2020 Aug 21.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 Aug 14.
 
The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. 2020 Jul 17.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Jul 20.

Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020: 370;M2980 

Remdesivir for severe covid-19: a clinical practice guideline. BMJ 2020: 370: M2924
 
Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11

Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Jun 24

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 08.

Severe Covid-19. N Engl J Med. 2020 May 15.

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569-1578.

Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 May 22.

Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Apr 10

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr 13

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020 Apr

Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020 Apr 17.

Guidance On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020 Apr 08.

Infographic for Principles of Airway Management in COVID-19. Hong Kong: Chinese University of Hong Kong; 2020

Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 06

Recommendations for investigational COVID-19 convalescent plasma. Silver Spring, MD: Food and Drug Administration. 2020 Apr 8.

COVID-19: early and emerging treatments. Open Forum Infect Dis. 2020 Mar 23.

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. Published online March 27, 2020

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering online 18 March 2020

A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19 N Engl J Med 2020 Mar 18[Online ahead of print]

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases Online ahead of print 9 Mar 2020

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care Available online 10 March 2020

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 International Journal of Antimicrobial Agents Online 4 March 2020

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma JAMA 2020 Mar 27[Online ahead of print]

The Cytokine Release Syndrome (CRS) of Severe COVID-19 and Interleukin-6 Receptor (IL-6R) Antagonist Tocilizumab May Be the Key to Reduce the Mortality
Int J Antimicrob Agents 2020 Mar 28[Online ahead of print]


COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression Lancet 395, 1033-1034 2020 Mar 28
 
Clinical Evidence Does Not Support Corticosteroid Treatment for 2019-nCoV Lung Injury Lancet, 395 (10223), 473-475

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease The Lancet Volume 395, Issue 10223, 15–21 February 2020, Pages e30-e31

First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382:929-936

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research volume 30, pages269–271(2020)

Non-invasive respiratory support for patients with novel coronavirus pneumonia clinical efficacy and reduction in risk of infection transmission Chinese Medical Journal: February 24, 2020 Publish Ahead of Print

Extracorporeal Membrane Oxygenation Support in 2019 Novel Coronavirus Disease: Indications, Timing, and Implementation Chin Med J 2020 Feb 28[Online ahead of print]

Reducing mortality from 2019-nCoV: host directed therapies should be an option. Lancet.2020;395(10224):e35-e6.
Top